ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital ...
Stockhead on MSN
Health Check: Biotechs canter into November, but the ‘favourites’ have lead in their saddlebags
The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback